CD4 and neoplasm: We found that CD3+, CD4+, CD8+ T cells increased per tumor weight in the aFP-treated groups (CD3/weight: control vs. aFP and control vs. aFP + anti-PD-1 (p < 0.005), anti-PD-1 vs. aFP and anti-PD-1 vs. aFP + anti-PD-1 (p < 0.05); CD4/weight: control vs. aFP, control vs. aFP + anti-PD-1, anti-PD-1 vs. aFP and anti-PD-1 vs. aFP + anti-PD-1 (p < 0.005); CD8/weight: control vs. aFP and control vs. aFP + anti-PD-1 (p < 0.005), anti-PD-1 vs. aFP and anti-PD-1 vs. aFP + anti-PD-1 (p < 0.05; Fig. 2a)).